Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Innoviva, Inc. - Common Stock (NQ:INVA)

20.51 -0.60 (-2.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Innoviva, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
3 Under-$20 Stocks That Could Make You a Fortune ↗
Discover three under-$20 stocks that could make a fortune in the pharmaceuticals, entertainment, and application software industries. 
Via InvestorPlace
News headline image
INVA Stock Earnings: Innoviva Beats EPS, Beats Revenue for Q1 2024 ↗
INVA stock results show that Innoviva beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva to Participate in the BofA Securities Health Care Conference
From Innoviva, Inc.
Via Business Wire
News headline image
A Look Into Healthcare Sector Value Stocks ↗
 
Via Benzinga
News headline image
5 Value Stocks In The Healthcare Sector ↗
 
Via Benzinga
News headline image
FDA's AdComm Panel Favors Innoviva's Drug For Multidrug-Resistant Bacterial Infections ↗
 
Via Benzinga
News headline image
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
From Innoviva Specialty Therapeutics
Via Business Wire
News headline image
5 Value Stocks In The Healthcare Sector ↗
 
Via Benzinga
News headline image
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names ↗
Biotech is one of the areas of interest in the market today, adding a biotech stock could be huge play this month. 
Via InvestorPlace
News headline image
Chart Of The Day: Innoviva - Individual Investor Favorite ↗
100% technical buy signals 14 new highs and up 12.87% in the last month 36.40+ Weighted Alpha 
Via Talk Markets
News headline image
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
From Innoviva Specialty Therapeutics
Via Business Wire
News headline image
A Look Into Healthcare Sector Value Stocks ↗
 
Via Benzinga
News headline image
Innoviva to Participate in the Cantor Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
News headline image
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Appoints Stephen Basso as Chief Financial Officer
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
Overview Of Value Stocks In The Healthcare Sector ↗
 
Via Benzinga
News headline image
Why These 7 Stocks Are the Best Ways to Play Biotech Right Now ↗
With biotech stocks offering myriad viable opportunities irrespective of broader conditions, this sector is worth a closer look. 
Via InvestorPlace
News headline image
Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
News headline image
AstraZeneca-Spin Off Entasis Secures FDA Approval For First Pathogen-Targeted Therapy Addressing Acinetobacter ↗
 
Via Benzinga
News headline image
Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use
From Innoviva, Inc.
Via Business Wire
News headline image
Over $125M Bet On Occidental Petroleum? Check Out These 4 Stocks Insiders Are Buying ↗
Although US stocks closed higher on Monday, there were a few notable insider trades. 
Via Benzinga
News headline image
Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
News headline image
Innoviva Announces Retirement of Board Chairman
From Innoviva, Inc.
Via Business Wire
News headline image
Elon Musk Says US Intel Agencies Had Access To Twitter DMs, Alibaba's Ant IPO Might Actually See Light, Airbus Pushes Some 2024 Deliveries: Today's Top Stories ↗
Benzinga Elon Musk Drops Bombshell: US Intel Agencies Were Reading Your Twitter DMs 
Via Benzinga
News headline image
Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee
From Innoviva, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.